Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Cesarina Giallongo 1, 2, * , Daniele Tibullo 1, 3, * , Nunziatina L. Parrinello 1 , Piera La Cava 1 , Michelino Di Rosa 2 , Vincenzo Bramanti 2 , Cosimo Di Raimondo 1 , Concetta Conticello 1 , Annalisa Chiarenza 1 , Giuseppe A. Palumbo 1 , Roberto Avola 2 , Alessandra Romano 1, * , Francesco Di Raimondo 1, * 1 Division of Hematology, A.O.U. Policlinico-OVE, Catania, University of Catania, Italy 2 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy 3 Department of Biological, Geological and Environmental Sciences, University of Catania, Catania, Italy * These authors contributed equally to this work Correspondence to: Daniele Tibullo, email: d.tibullo@unict.it Keywords: MM microenvironemnt, mesenchymal stem cells, G-MDSC, immune-suppression Received: October 30, 2015 Accepted: February 05, 2016 Published: March 07, 2016 ABSTRACT Granulocytic-Myeloid-derived suppressor cells (G-MDSC) are increased in Multiple Myeloma (MM) patients but the mechanisms of G-MDSC generation are still unknown. There are many evidences of the role of mesenchymal stem cells (MSC) in promoting MM cell growth, survival and drug-resistance. We here used a specific experimental model in vitro to evaluate the ability of MSC to induce G-MDSC. We found that although MSC derived from healthy donors (HD), MGUS and MM were able to generate the same amount of MDSC, only MM-MSC-educated G-MDSC exhibited suppressive ability. In addition, in comparison with MSC derived from HD, MM-MSC produce higher amount of immune-modulatory factors that could be involved in MDSC induction. Compared to G-MDSC obtained from co-culture models with MSC from healthy subjects, both MGUS and MM-MSC-educated G-MDSC showed increase of immune-modulatory factors. However, only MM-MSC educated G-MDSC 1) up-regulated immune-suppressive factors as ARG1 and TNFα, 2) expressed higher levels of PROK2, important in angiogenesis and inflammatory process, and 3) showed ability to digest bone matrix. Our data demonstrate that MM-MSC are functionally different from healthy subjects and MGUS-MSC, supporting an evolving concept regarding the contribution of MM-MSC to tumor development and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In many cancers, it has been demonstrated that tumor-associated microenvironment produces a large amount of immune-modulating factors involved in reprogramming immature myeloid cells to become immunosuppressive G-MDSC and to attract them at the tumor sites [36].”
BackgroundAn interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“PROK2 is a key regulator of inflammation-dependent tumorigenesis promoting chemotaxis, angiogenesis [38, 52] and drug-resistance into the tumor microenvironment [53].”
BackgroundBone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107 · cited 1×
“When compared with their normal counterparts, MM-MSC differ in cytokine production, show a decreased proliferative ability with a premature senescence profile [42] and reduced capacity to inhibit T cell proliferation [43].”
Result
Cited by
Li, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., Wang, B., Wang, Q., Zhao, Y., & Cai, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106939 · Cited by 381
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
“Moreover, the myeloma niche is immunosuppressive, as the activity of myeloid-derived suppressor cells (MDSCs), which secrete IL-10 and TGF-b (45), is enhanced by the production of IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) by MM cells.”
BackgroundBone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
“, Arginase1 and TNFα) [49] and increased ability to digest bone matrix [202].”
Background
Metadata
- Authors
- Giallongo, C., Tibullo, D., Parrinello, N. L., La Cava, P., Di Rosa, M., Bramanti, V., Di Raimondo, C., Conticello, C., Chiarenza, A., Palumbo, G. A., Avola, R., Romano, A., & Di Raimondo, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-07
- Volume
- 7
- Issue
- 52
- Pages
- 85764-85775
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2295129153
- Cited by
- 100
- References
- 6
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.